Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 3
2011 1
2012 2
2014 3
2015 2
2016 6
2017 7
2018 9
2019 6
2020 7
2021 5
2022 3
2023 5
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Tumour-agnostic therapies.
Looney AM, Nawaz K, Webster RM. Looney AM, et al. Among authors: webster rm. Nat Rev Drug Discov. 2020 Jun;19(6):383-384. doi: 10.1038/d41573-020-00015-1. Nat Rev Drug Discov. 2020. PMID: 32494047 No abstract available.
The endometrial carcinoma market.
Vinuesa L, Webster RM. Vinuesa L, et al. Among authors: webster rm. Nat Rev Drug Discov. 2022 Apr;21(4):255-256. doi: 10.1038/d41573-022-00016-2. Nat Rev Drug Discov. 2022. PMID: 35064241 No abstract available.
Bispecific antibodies in oncology.
Esfandiari A, Cassidy S, Webster RM. Esfandiari A, et al. Among authors: webster rm. Nat Rev Drug Discov. 2022 Jun;21(6):411-412. doi: 10.1038/d41573-022-00040-2. Nat Rev Drug Discov. 2022. PMID: 35246638 No abstract available.
The malignant melanoma market.
Parra LM, Webster RM. Parra LM, et al. Among authors: webster rm. Nat Rev Drug Discov. 2022 Jul;21(7):489-490. doi: 10.1038/d41573-022-00075-5. Nat Rev Drug Discov. 2022. PMID: 35477778 No abstract available.
The hepatocellular carcinoma market.
Dawkins J, Webster RM. Dawkins J, et al. Among authors: webster rm. Nat Rev Drug Discov. 2019 Jan;18(1):13-14. doi: 10.1038/nrd.2018.146. Epub 2018 Aug 31. Nat Rev Drug Discov. 2019. PMID: 30168534 No abstract available.
The breast cancer drug market.
Wilcock P, Webster RM. Wilcock P, et al. Among authors: webster rm. Nat Rev Drug Discov. 2021 May;20(5):339-340. doi: 10.1038/d41573-021-00018-6. Nat Rev Drug Discov. 2021. PMID: 33483705 No abstract available.
The prostate cancer drug market.
do Pazo C, Webster RM. do Pazo C, et al. Among authors: webster rm. Nat Rev Drug Discov. 2021 Sep;20(9):663-664. doi: 10.1038/d41573-021-00111-w. Nat Rev Drug Discov. 2021. PMID: 34145436 No abstract available.
The oncology market for antibody-drug conjugates.
do Pazo C, Nawaz K, Webster RM. do Pazo C, et al. Among authors: webster rm. Nat Rev Drug Discov. 2021 Aug;20(8):583-584. doi: 10.1038/d41573-021-00054-2. Nat Rev Drug Discov. 2021. PMID: 33762691 No abstract available.
The non-small-cell lung cancer drug market.
Nawaz K, Webster RM. Nawaz K, et al. Among authors: webster rm. Nat Rev Drug Discov. 2023 Apr;22(4):264-265. doi: 10.1038/d41573-023-00017-9. Nat Rev Drug Discov. 2023. PMID: 36690751 No abstract available.
The SCCHN drug market.
Bamford J, Webster RM. Bamford J, et al. Among authors: webster rm. Nat Rev Drug Discov. 2017 Apr;16(4):235-236. doi: 10.1038/nrd.2016.261. Epub 2017 Jan 13. Nat Rev Drug Discov. 2017. PMID: 28082745 No abstract available.
64 results